Research programme: cancer therapeutics - Glactone Pharma

Drug Profile

Research programme: cancer therapeutics - Glactone Pharma

Alternative Names: GPA 500; GPB 600-ER; GPB 600-IO

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glactone Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer
  • Research Cancer

Most Recent Events

  • 09 May 2017 Glactone Pharma has patent protection entitled “Ether analogues of galiellalactone” in Sweden
  • 30 Jan 2017 Early research in Cancer in Sweden before January 2017 (Glactone Pharma pipeline, January 2017)
  • 30 Jan 2017 Early research in Prostate cancer (Second-line therapy or greater) in Sweden before January 2017 (Glactone Pharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top